Antibacterial Drugs Analysis by Drug Class (?-lactam, Quinolone, Macrolide, Tetracycline Antibacterial Drugs), by Route of Administration (Enteral, Parenteral Antibacterial Drug Administration), by Distribution Channel, by Region - Global Insights 2021 to 2031

Market Outlook for Antibacterial Drugs

According to Fact.MR’s recent study on the global antibacterial drugs market, the market is projected to expand at a CAGR of 2.6% over the forecast period (2021-2031), and reach a valuation of over US$ 62 Bn by 2031-end, and surpassing US$ 51 Bn by 2025. As of the next half-a-decade, the market is anticipated to register a CAGR of 1.5%. Demand for β-lactams will be the highest, clocking a CAGR of 2% through 2031.

Points Covered in Antibacterial Drugs Industry Survey

• Market Estimates and Forecasts (2016-2031)
• Key Drivers and Restraints Shaping Market Growth
• Segment-wise, Country-wise, and Region-wise Analysis
• Competition Mapping and Benchmarking
• Brand Share and Market Share Analysis
• Key Product Innovations and Regulatory Climate
• Assessment by Product Grade / Purity / Formulation Standards
• Assessment of Import Price, Bulk Price, Contractual Price, Producer / Distributor Price
• Certifications and Compliance Requirements
• COVID-19 Impact on the Antibacterial Drugs Industry and How to Navigate
• Recommendation on Key Winning Strategies

Consumption Analysis of Antibacterial Drugs 2016-2020 Vs Outlook 2021-2031

As per Fact.MR – a market research and competitive intelligence provider, during the historic period of 2016 to 2020, the market for antibacterial drugs registered sluggish growth, expanding at around 1% CAGR. Ongoing research to develop powerful formulation owing to rising antibiotic resistance has led to the launch of a limited number of drugs into the market.

Growth prospects took a backseat amidst the COVID-19 pandemic, as healthcare providers redirected funding and research towards developing anti-COVID vaccinations and drugs. Although several nations have inoculated their population, an oral drug is expected to take a significant amount of time to be introduced, which may cause a slowdown in the scope for formulating antibacterials.

Considering these factors, Fact.MR projects the global market for antibacterial drugs to expand at a CAGR of 2.6% across the forecast period 2021-2031. As per the report, the industry is poised to reach US$ 62 Bn by the end of the aforementioned period.

How will R&D Activities Drive Market Growth of Antibacterial Drugs?

All the developed and emerging economies are conducting various research and development activities for the new anti-bacterial drug development. Governments have been regulating the testing of the efficacy and safety of the newly developed antibacterial drugs. 

For instance, Clinical Trials Transformative Initiative (CTTI) has created approaches for streamlining antibacterial drug development that will help in designing clinical trials that better assess the efficacy and safety of new antibacterial drugs and inform clinical trial planning, recruitment, enrollment, and feasibility.

Are E-Pharmacies Propelling the Market for Antibacterial Drugs?

The market for antibacterial drugs is witnessing substantial growth, with a relatively slim drug pipeline further dampening market prospects. However, conscientious efforts taken by the governments of numerous countries, especially in Europe and North America, are projected to lead to an upsurge in the development of branded drugs.

For instance, in February 2021, the U.S. Food and Drug Administration announced the creation of the Center of Drug Evaluation and Research (CDER) Antibacterial Drug Development Task Force to support the development of new antibacterial drugs. 

Also, e-pharmacies will be a full-fledged distribution channel in the future, which will enable next-day/same-day delivery, and help validate the credibility of prescriptions. An estimated 1 in 10 medical products circulating in low- and middle-income countries is either substandard or falsified, according to new research from World Health Organization.

E-Pharmacies ensure a genuine drug supply, sourcing it directly from manufacturers and licensed resellers. E-retailers conform to government regulations, which further increases the reliance of patients on e-pharmacies.  Given the rise of this new revenue stream, the market will register a healthy growth rate.

Country-Wise Analysis

Why is North America a Lucrative Market for Antibacterial Drugs?

North America is projected to dominate the global market during the forecast period owing to a highly structured health care industry, increasing prevalence of infectious diseases, and introduction of novel products in the region. 

Furthermore, regional incidence of antimicrobial resistant infections are surging manifold. The Centers for Disease Control and Prevention estimates that at least 2.8 million people contract an antibiotic-resistant infection, with more than 35,000 fatalities each year.

Consequently, healthcare providers are working ceaselessly to develop advanced formulations. As of 2020, the Infectious Diseases Society of America (IDSA) has been working on the 10 x 20 initiative, seeking a global commitment to create an antibiotic R&D enterprise to produce 10 new systematic antibiotics by the end of that year. The region will likely account for 33% market demand.

How is Asia Projected to Perform in the Market for Antibacterial Drugs?

Fact.MR forecasts the Asian market for antibacterial drugs to exhibit the dominant market share, accounting for 50% of total revenue. Factors such as increasing patient population, initiatives by the developing economies in the healthcare sector, rising geriatric population, and growing incidence of infectious diseases are spurring adoption in the region.

Japan holds significant opportunities for the market players, on the back of a large patient pool that includes the geriatric population, coupled with a well-established distribution network. Besides this, given the technological advancements in Japan, e-pharmacies will remain an integral sales channel in the future. Numerous companies such as Aspen Pharma Holdings, Sun Pharmaceuticals, and Lupin continue to invest in Japan to cash in on the profitable opportunities available in this market. 

What are the Growth Prospects across Europe?

Demand for novel and effective drugs, on account of progressive acceptance of the out-of-pocket payment model, is projected to draw high sales possibilities. The low cost of generic drugs will continue to fuel market growth in the region during the forecast period.

In 2020, the European Commission announced a Pharmaceutical Strategy for Europe which offers a unique opportunity to deliver a policy that provides EU citizens with medicines that bring additional therapeutic benefits at a price they are able to pay.

Europe’s pharmaceutical sector contributes majorly to the EU economy in terms of creation of highly skilled jobs and innovation. In addition to this, digitalization and innovation are opening new possibilities. Fact.MR expects the European market to capture around 35% of the revenue.

Category-wise Insights

Which Drug Class is projected to Witness the Highest Demand?

There has been a marked uptake in the sales of β-lactam, as these are indicated for the prevention and treatment of bacterial infections. Continuous progression in the development of effective β-lactam is deemed as a primary growth indicator of this drug class.

For example, initially, β-lactam drugs were active only against gram-positive bacteria. However, in recent times, these are showing resistance against gram-negative organisms as well, which is expected to further drive their popularity. The segment is poised to register a CAGR of over 2% until 2031.

How are Retail Pharmacies Creating Opportunities?

The retail pharmacies and drug stores segment is anticipated to grow significantly during the forecast period owing to the increasing number of retail drugs stores, and the availability of antibacterial drugs through retail pharmacies and drugs stores.

Currently, e-pharmacies witness challenges, such as non-compliance of e-retailers with government regulations, concerns regarding the credibility of prescription, drug counterfeiting, and delay in shipping. However, in the future, this distribution channel will remain integral in driving sales from overseas markets. The segment is expected to account for over 40% revenue.

Competitive Landscape  

Competition in the global market for antibacterial drugs is expected to rise, with players focusing on gaining competitive advantage and increasing their market foothold. Manufacturers can seek partnerships with government organizations to gain financial support for the development of drugs, and, in turn, position themselves as distinguished players in the global market.

• In September 2021, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis.

• In July 2021, AstraZeneca announced that it has entered into a collaboration with Regeneron to research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.

Report Scope 

Key Segments Covered

• Drug Class

  • β-lactam Antibacterial Drugs
  • Quinolone Antibacterial Drugs
  • Macrolide Antibacterial Drugs
  • Tetracycline Antibacterial Drugs
  • Aminoglycoside Antibacterial Drugs
  • Sulfonamide Antibacterial Drugs
  • Phenicols Antibacterial Drugs
  • Other Antibacterial Drugs

• Route of Administration

  • Enteral Antibacterial Drug Administration
  • Parenteral Antibacterial Drug Administration
  • Other Antibacterial Drug Administration Routes (Inhalation, Topical, etc.)

• Distribution Channel

  • Antibacterial Drug Sales via Hospital Pharmacies
  • Antibacterial Drug Sales via Drug Stores and Retail Pharmacies
  • Online Antibacterial Drug Sales